Insmed, Inc.
$120.00
-$3.98 (-3.21%)
$119.32Day Range$124.11
Key Statistics
Market Cap
$27.07B
Shares Outstanding
218.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 1, 2000
Round Lot
100
Locale
US
Trading Data
Day Open
$123.89
Day High
$124.11
Day Low
$119.32
Volume
3.45M
VWAP
$120.82
Prev Close
$123.98
Transactions
--
Acc. Volume
--
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
PHARMACEUTICAL PREPARATIONSSIC 28341,664 employees700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807908-977-9900IPO Jun 1, 2000US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001104506
- Composite FIGI
- BBG000BWM5P3
- Share Class FIGI
- BBG001S9SKW7
- Ticker Root
- INSM
- SIC Code
- 2834
About Insmed, Inc. (INSM) Stock
Insmed, Inc. (INSM) closed the 2026-09-18 session at $120.00, down 3.21% versus the previous close (-3.98). The stock opened at $123.89 and traded between $119.32 and $124.11 during that session. Session trading volume was 3.4M shares. The volume-weighted average price (VWAP) is $120.82.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed, Inc. has a market capitalization of $27.07 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. INSM is listed on the XNAS exchange. The company employs approximately 1,664 people. Insmed, Inc. is headquartered in BRIDGEWATER, NJ. The recorded listing date is 2000-06-01.
On this page you can find market INSM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.